Strides Pharma Science Ltd
Strides Pharma Science Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
What the Q4 FY26 call signalled
1 of 3 strong
Not discussed on this call: fundraise, order book.
The short version
U.S. Strides expects sequential quarter-on-quarter growth, continuing the trend seen in FY26 Q4 with 11% growth (14% excluding institutional business).
From Strides Pharma Science Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- U.S. business growth expected to accelerate from H2 FY27 onwards with new product launches, including nasal sprays and controlled substances.
- Targeted U.S. revenue aspiration of $375 million to $400 million by FY28, representing about 15%-20% CAGR from current base.
- Controlled substances business is a new growth engine; additional quota allocations pending with DEA may drive future growth.
- Nasal sprays and complex generics (transdermals, films) expected to contribute meaningfully from FY28 and FY29 onwards.
- Ex-U.S. markets showing strong, consistent growth with 21% CAGR in FY26 and growing faster than the U.S. market.
- Product launches and portfolio rationalization strategies focus on profitability and sustainable revenue growth.
- Growth drivers include expanded global R&D, strategic partnerships, and deeper penetration in key regulated and emerging markets.
Profitability & Margins
See what Strides Pharma Science Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Total capital investments in FY26 were INR418 crores, including:
- - INR236 crores tangible capex focused on:
- - Nasal spray capabilities development
- - Enhancing capacities for Ex-U.S. business
- - Acquisition of new office space in the U.K.
- - INR182 crores intangible investments covering:
- - Acquisition of global product rights to drive growth in U.S. and Ex-U.S. markets
- - Significant upgrade to global ERP platform migrating to SAP HANA
- Future capex run rate expected around INR300 crores annually over next 2 years:
- - Tangible capex largely maintenance capex after recent growth investments
- - Intangible investments expected to continue for acquiring global rights and fast-tracking growth
- Investments in complex generics like nasal sprays, transdermals, and films targeting meaningful revenue from FY28 onwards
- Acquisition of certain Sandoz products in Feb '26 to strengthen presence in Africa starting H2 FY27
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Strides Pharma Science Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Strides Pharma Science Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.3K Cr, net profit ₹129 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Strides Pharma Science Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Torrent Pharmaceuticals Ltd (Q4 FY26)
Consolidated revenue for Q4 FY26 up 42%, EBITDA up 41%, margins stable at ~32% (Page 2). Key concall takeaways from Torrent Pharma.'s Q4 FY26 earnings call…
- Kwality Pharmaceuticals Ltd (Q4 FY26)
FY26: Achieved INR503 crores revenue; oncology contributed INR100-120 crores. Key concall takeaways from Kwality Pharmaceuticals Ltd's Q4 FY26 earnings call…
- RPG Life Sciences Ltd (Q4 FY26)
Domestic formulation growth driven by strong volume expansion (~9.8% volume growth in Q4 FY26 vs 1.1% industry) and new product launches (5.1% growth vs 2%…
- Sai Parenterals Ltd (Q4 FY26)
Long-term growth supported by over 50% revenue from long-term CDs contracts in regulated markets. Key concall takeaways from Sai Parenteral's's Q4 FY26…
Frequently Asked Questions
What were Strides Pharma Science Ltd Q4 FY26 results?
U.S. Strides expects sequential quarter-on-quarter growth, continuing the trend seen in FY26 Q4 with 11% growth (14% excluding institutional business).
What is Strides Pharma Science Ltd share price analysis?
Strides Pharma Science Ltd currently shows a below-average growth signal. The stock trades at a P/E of 15.4 with a market cap of ₹8,944 Cr. Investors should review the full earnings analysis for detailed insights.
Is Strides Pharma Science Ltd planning capital expenditure?
Total capital investments in FY26 were INR418 crores, including: - INR236 crores tangible capex focused on: - Nasal spray capabilities development - Enhancing capacities for Ex-U.S.
Keep Strides Pharma Science Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.